Fluzoparib clinical trials
Fluzoparib is named as an intervention in 20 current clinical trials in our China, UK, USA, France, Spain, Belgium, Poland, Czechia, South Korea, Taiwan and Australia registers. 15 are recruiting patients now. The most common phase is Phase 2. The sponsor with the most trials is Fudan University (5). The most-studied condition is Ovarian Cancer.
How Fluzoparib works
All drug targets →- Breast cancerPhase 3
- Fallopian tube cancerPhase 3
- Malignant pancreatic neoplasmPhase 3
- Ovarian cancerPhase 3
- Ovarian carcinomaPhase 3
- Pancreatic neoplasmPhase 3
- Primary peritoneal carcinomaPhase 3
- Prostate cancerPhase 3
- Triple-negative breast carcinomaPhase 3
- Ewing sarcomaPhase 2
Mechanisms and diseases from ChEMBL via the Open Targets Platform (release 26.09), ChEMBL record CHEMBL3930624, CC BY-SA 3.0. Targets checked against the IUPHAR/BPS Guide to PHARMACOLOGY (2026.3.1), ligand 13763, CC BY-SA 4.0. Trial phases are not approvals: approved uses are shown from the regulators' own records where we hold them.
Patient leaflets for Fluzoparib
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Trials by status
Trials by phase
Clinical trials of Fluzoparib
20 trialsRegisters list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Conditions studied with Fluzoparib
30 conditionsAll 30 conditions
| Condition (as registered) | Trials |
|---|---|
| Ovarian Cancer | 5 |
| Breast Cancer | 3 |
| Breast Neoplasm | 2 |
| Triple-Negative Breast Cancer (TNBC) | 2 |
| Breast Cancer Metastatic | 2 |
| Metastatic Castration-Resistant Prostate Cancer (mCRPC) | 1 |
| Hormone Receptor Positive Tumor | 1 |
| HER2-negative Breast Cancer | 1 |
| Sarcoma,Soft Tissue | 1 |
| Brachytherapy | 1 |
| Poly(ADP-ribose) Polymerase Inhibitors | 1 |
| Advanced Solid Tumors | 1 |
| Platinum-sensitive | 1 |
| TNBC, Triple Negative Breast Cancer | 1 |
| BRCA1/2 Mutation or Not | 1 |
| Breast Tumors | 1 |
| High Grade Serous Adenocarcinoma of Ovary | 1 |
| High Grade Endometrioid Ovarian Cancer | 1 |
| Primary Peritoneal Cancer | 1 |
| Fallopian Tube Cancer | 1 |
| Peritoneal Cancer | 1 |
| Germline BRCA-mutated HER2-negative Breast Cancer | 1 |
| Fludzoparib" and Anti-angiogenic | 1 |
| HRD-positive/HER2-negative Advanced Breast Cancer | 1 |
| Ewing Sarcoma | 1 |
| Endometrial Carcinoma | 1 |
| TP53 Mutation | 1 |
| Recurrent or Metastatic | 1 |
| Her-2 Negative Breast Cancer | 1 |
| HRR Gene Mutation | 1 |
Sponsors
lead sponsor per trialBy country register
A trial with sites in more than one country appears in each of those registers.
Related compounds
Questions about Fluzoparib trials
How many clinical trials are testing Fluzoparib?
20 current trials in our China, UK, USA, France, Spain, Belgium, Poland, Czechia, South Korea, Taiwan and Australia registers name Fluzoparib (also registered as SHR3162) as a drug or biological intervention, as of the registry sync on 9 November 2026. Completed and withdrawn studies are not counted.
Are Fluzoparib trials recruiting patients?
Yes. 15 of the 20 trials are recruiting: 15 with sites in China. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Who sponsors Fluzoparib clinical trials?
Fudan University (5), Tongji Hospital (2), Sun Yat-sen University (2) and Jiangsu HengRui Medicine Co., Ltd (1), among 14 lead sponsors in total. The number in brackets is how many trials each organisation leads.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Fluzoparib works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Fluzoparib works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Fluzoparib (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 9 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.